Hoth Rebrands to Rocket One, Targets AI Semiconductor Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 19 2026
0mins
Source: PRnewswire
- Strategic Restructuring: Hoth has announced its rebranding to Rocket One and is restructuring its business through a wholly-owned subsidiary to focus on artificial intelligence infrastructure and next-generation semiconductor technologies, aiming to capitalize on the rapidly growing AI market.
- Exclusive Technology Licensing: The company has secured exclusive rights to AI acceleration technology based on non-volatile nanomagnetic semiconductor architecture and spintronic computing technologies, which are expected to significantly enhance energy efficiency and computing performance, addressing current power consumption challenges in AI infrastructure.
- Market Potential: As global demand for large language models and generative AI surges, Rocket One's technologies are poised to provide strong competitive advantages in the AI semiconductor market, potentially driving future revenue growth for the company.
- Biotechnology Continuation: The company plans to place its biotechnology assets into a separate subsidiary to preserve their value while allowing the parent company to focus on the rise of AI semiconductor infrastructure, demonstrating a forward-looking approach to future technological developments.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HOTH?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HOTH
About HOTH
Rocket One Inc., formerly Hoth Therapeutics, Inc., is focused on developing and commercializing infrastructure for the orbital economy, including nanomagnetic AI chip technology designed for radiation-tolerant, energy-constrained environments such as low-Earth orbit, deep-space platforms, and defense systems. The Company holds exclusive rights to certain technologies, including a nanomagnetic matrix multiplier architecture intended as a hardware accelerator for machine learning and AI workloads, and related magnetic memory technology with potential applications in radiation-tolerant computing for defense and space systems. The Company is also positioned to pursue opportunities in nano-launch systems and nanosatellite deployment. The Company's biotechnology pipeline includes HT-001, HT-KIT, HT-ALZ, and GDNF-based metabolic program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
NASA Chief Warns of Uncertain Commercial Demand in Space Economy
- Demand Warning: NASA Chief Jared Isaacman cautioned that commercial demand in the orbital economy has been 'grossly overstated,' emphasizing that government remains the primary source of demand, which could impact future investor confidence.
- Space Stock Surge: Following NASA's announcement of near-monthly lunar missions starting in 2027, shares of Momentus (MNTS) jumped 26%, while Astrotech (ASTC) skyrocketed 459%, reflecting strong market interest and investment enthusiasm in space exploration.
- Funding and Growth: Momentus raised $25 million through a private placement, expecting to hold $76 million in cash, supporting its operations in in-space logistics and orbital transportation systems, highlighting its significance in NASA and defense contracts.
- Future Computing Opportunities: Astrotech is exploring future opportunities for lunar resources and infrastructure, including water extraction and rare material processing, indicating the company's long-term strategic focus on space computing and quantum systems.
See More
NASA Chief Warns of Uncertain Commercial Demand in Space Economy
- Lunar Mission Plans: NASA outlines plans for near-monthly robotic lunar missions starting in 2027, with a projected $20 billion investment over seven years for infrastructure, although Administrator Isaacman cautions that commercial demand remains uncertain and heavily reliant on government support.
- SpaceX IPO Hype: With SpaceX targeting a $2 trillion valuation, potentially making it the first trillion-dollar IPO in U.S. history, investor excitement has surged, although the company's near-term profitability remains unclear, raising questions about sustainable demand in the space sector.
- Momentus Financing Update: Momentus has raised $25 million through a private placement, expecting to hold around $76 million in cash, with insider purchases from former astronaut Hadfield boosting market confidence and driving a 26% stock price increase in a short period.
- Astrotech and RKTO Prospects: Astrotech is exploring lunar resource development, while RKTO focuses on orbital computing and defense technology, with stock prices soaring 459% and 92% respectively, indicating strong market interest in space technology advancements.
See More
Hoth Transforms into Rocket One, Shares Surge 80%
- Stock Surge: Hoth Therapeutics, Inc. (HOTH) shares surged 80% on Wednesday following the announcement of its transformation into Rocket One, breaking above the 200-day moving average for the first time in over two months, indicating strong market approval of its new strategy.
- New Ticker Symbol: The company will begin trading under the new ticker symbol RKTO on Nasdaq starting May 28, replacing the current HOTH symbol, marking a significant shift towards its focus on the orbital economy.
- Exclusive Technology Rights: Hoth recently secured exclusive rights to nanomagnetic AI chip technology designed for ultra-low-power computing and high-radiation environments, which is expected to significantly enhance its applications in satellites and defense systems.
- Market Sentiment Shift: Following Hoth's pivot announcement, retail sentiment on Stocktwits flipped to 'extremely bullish', reflecting strong market anticipation for its new business strategy, although a major deal will be necessary to sustain the current stock momentum.
See More
Hoth Therapeutics Rebrands to Rocket One, Adopts New Ticker RKTO
- Corporate Rebranding: Hoth Therapeutics officially rebranded to Rocket One Inc. on May 26, 2026, and will begin trading under the new ticker RKTO on May 28, 2026, reflecting a strategic shift towards the orbital economy focused on satellite and defense platform development.
- Exclusive Technology Rights: Rocket One has secured exclusive rights to next-generation nanomagnetic AI chip technology, which is particularly suited for operation in low Earth orbit and high-radiation environments, expected to enhance the company's competitiveness in the rapidly growing commercial space market.
- Market Opportunities: With the rise of small satellites and defense demand, Rocket One plans to leverage its technology platform to focus on AI chips, nano-launch systems, and defense applications, believing these markets are mutually reinforcing and will provide substantial growth potential.
- Management Outlook: CEO Robb Knie stated that the rebranding reflects the company's positioning in the orbital economy, emphasizing that the next decade will be defined by platforms capable of autonomous operation under power and radiation constraints, showcasing confidence to investors and partners.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which is expected to enhance its market competitiveness in allergic and inflammatory diseases.
- Scientific Validation: CEO Robb Knie stated that this allowance serves as a significant validation of the science underlying their mast cell platform, further strengthening the intellectual property foundation of the HT-KIT program, which may drive future clinical research and product development.
- IND Submission Plans: Hoth expects to finalize its IND submission for the HT-KIT program in 2026, followed by first-in-human studies, which will lay the groundwork for innovative treatments in mast cell-driven diseases.
- Subsidiary Structure Adjustment: The company is exploring placing its biotechnology pipeline and therapeutic development projects under a separate wholly-owned subsidiary to preserve the value of its biotechnology portfolio while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic program has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which strengthens the company's intellectual property foundation in the biopharmaceutical sector.
- Technological Innovation: The allowed antisense oligomers aim to reduce cell-surface expression of the high-affinity IgE receptor, providing a novel therapeutic mechanism distinct from traditional antihistamines and small-molecule inhibitors, potentially offering better efficacy in allergic and inflammatory diseases.
- Broad Indication Coverage: The allowed method claims span various diseases, including asthma, atopic dermatitis, and allergic conjunctivitis, indicating the HT-KIT program's extensive potential in treating mast cell-driven diseases, which may open new market opportunities for the company.
- Strategic Restructuring Plan: Hoth is exploring placing its biotechnology pipeline and therapeutic development programs under a wholly owned subsidiary to better manage resources and protect shareholder value while continuing to pursue emerging opportunities in AI semiconductor infrastructure and advanced computing technologies.
See More
NASA Chief Warns of Uncertain Commercial Demand in Space Economy
- Demand Warning: NASA Chief Jared Isaacman cautioned that commercial demand in the orbital economy has been 'grossly overstated,' emphasizing that government remains the primary source of demand, which could impact future investor confidence.
- Space Stock Surge: Following NASA's announcement of near-monthly lunar missions starting in 2027, shares of Momentus (MNTS) jumped 26%, while Astrotech (ASTC) skyrocketed 459%, reflecting strong market interest and investment enthusiasm in space exploration.
- Funding and Growth: Momentus raised $25 million through a private placement, expecting to hold $76 million in cash, supporting its operations in in-space logistics and orbital transportation systems, highlighting its significance in NASA and defense contracts.
- Future Computing Opportunities: Astrotech is exploring future opportunities for lunar resources and infrastructure, including water extraction and rare material processing, indicating the company's long-term strategic focus on space computing and quantum systems.
See More
NASA Chief Warns of Uncertain Commercial Demand in Space Economy
- Lunar Mission Plans: NASA outlines plans for near-monthly robotic lunar missions starting in 2027, with a projected $20 billion investment over seven years for infrastructure, although Administrator Isaacman cautions that commercial demand remains uncertain and heavily reliant on government support.
- SpaceX IPO Hype: With SpaceX targeting a $2 trillion valuation, potentially making it the first trillion-dollar IPO in U.S. history, investor excitement has surged, although the company's near-term profitability remains unclear, raising questions about sustainable demand in the space sector.
- Momentus Financing Update: Momentus has raised $25 million through a private placement, expecting to hold around $76 million in cash, with insider purchases from former astronaut Hadfield boosting market confidence and driving a 26% stock price increase in a short period.
- Astrotech and RKTO Prospects: Astrotech is exploring lunar resource development, while RKTO focuses on orbital computing and defense technology, with stock prices soaring 459% and 92% respectively, indicating strong market interest in space technology advancements.
See More
Hoth Transforms into Rocket One, Shares Surge 80%
- Stock Surge: Hoth Therapeutics, Inc. (HOTH) shares surged 80% on Wednesday following the announcement of its transformation into Rocket One, breaking above the 200-day moving average for the first time in over two months, indicating strong market approval of its new strategy.
- New Ticker Symbol: The company will begin trading under the new ticker symbol RKTO on Nasdaq starting May 28, replacing the current HOTH symbol, marking a significant shift towards its focus on the orbital economy.
- Exclusive Technology Rights: Hoth recently secured exclusive rights to nanomagnetic AI chip technology designed for ultra-low-power computing and high-radiation environments, which is expected to significantly enhance its applications in satellites and defense systems.
- Market Sentiment Shift: Following Hoth's pivot announcement, retail sentiment on Stocktwits flipped to 'extremely bullish', reflecting strong market anticipation for its new business strategy, although a major deal will be necessary to sustain the current stock momentum.
See More
Hoth Therapeutics Rebrands to Rocket One, Adopts New Ticker RKTO
- Corporate Rebranding: Hoth Therapeutics officially rebranded to Rocket One Inc. on May 26, 2026, and will begin trading under the new ticker RKTO on May 28, 2026, reflecting a strategic shift towards the orbital economy focused on satellite and defense platform development.
- Exclusive Technology Rights: Rocket One has secured exclusive rights to next-generation nanomagnetic AI chip technology, which is particularly suited for operation in low Earth orbit and high-radiation environments, expected to enhance the company's competitiveness in the rapidly growing commercial space market.
- Market Opportunities: With the rise of small satellites and defense demand, Rocket One plans to leverage its technology platform to focus on AI chips, nano-launch systems, and defense applications, believing these markets are mutually reinforcing and will provide substantial growth potential.
- Management Outlook: CEO Robb Knie stated that the rebranding reflects the company's positioning in the orbital economy, emphasizing that the next decade will be defined by platforms capable of autonomous operation under power and radiation constraints, showcasing confidence to investors and partners.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which is expected to enhance its market competitiveness in allergic and inflammatory diseases.
- Scientific Validation: CEO Robb Knie stated that this allowance serves as a significant validation of the science underlying their mast cell platform, further strengthening the intellectual property foundation of the HT-KIT program, which may drive future clinical research and product development.
- IND Submission Plans: Hoth expects to finalize its IND submission for the HT-KIT program in 2026, followed by first-in-human studies, which will lay the groundwork for innovative treatments in mast cell-driven diseases.
- Subsidiary Structure Adjustment: The company is exploring placing its biotechnology pipeline and therapeutic development projects under a separate wholly-owned subsidiary to preserve the value of its biotechnology portfolio while enabling the parent company to pursue emerging opportunities in AI semiconductor infrastructure.
See More
Hoth Therapeutics Secures Patent Allowance for HT-KIT Program
- Patent Allowance Announcement: Hoth Therapeutics announced that its HT-KIT therapeutic program has received a Notice of Allowance from the USPTO, covering antisense oligomers targeting MS4A6A pre-mRNA splicing, which strengthens the company's intellectual property foundation in the biopharmaceutical sector.
- Technological Innovation: The allowed antisense oligomers aim to reduce cell-surface expression of the high-affinity IgE receptor, providing a novel therapeutic mechanism distinct from traditional antihistamines and small-molecule inhibitors, potentially offering better efficacy in allergic and inflammatory diseases.
- Broad Indication Coverage: The allowed method claims span various diseases, including asthma, atopic dermatitis, and allergic conjunctivitis, indicating the HT-KIT program's extensive potential in treating mast cell-driven diseases, which may open new market opportunities for the company.
- Strategic Restructuring Plan: Hoth is exploring placing its biotechnology pipeline and therapeutic development programs under a wholly owned subsidiary to better manage resources and protect shareholder value while continuing to pursue emerging opportunities in AI semiconductor infrastructure and advanced computing technologies.
See More
